Ads
related to: what is aminoglycoside therapy for diabetes 1- See the FAQs
Get the Answers to Frequently
Asked Questions Today.
- View Patient Stories
Watch Videos of Patient Stories
Today to Start Your T1D Journey.
- Join the Support Program
View Resources & Copay Assistance.
Terms & Conditions Apply.
- Talk to Your Doctor
Download the Discussion Guide
to Start the Conversation Today.
- Get Screened Today
Discover the Importance of Early
Screening. Learn More Now.
- View T1D Organizations
Stay Connected. Learn About
T1D Organizations Today.
- See the FAQs
Search results
Results From The WOW.Com Content Network
Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside . [1] [2] The term can also refer more generally to any organic molecule that contains amino sugar substructures.
In patients with diabetes mellitus type 1, alpha-glucosidase inhibitors use has not been officially approved by the Food and Drug Administration in the US but some data exists on the effectiveness in this population, showing potential benefits weighted against an increased risk of hypoglycemia. [18]
Type 1 diabetes is a disease caused by the lack of insulin. Thus, insulin is the main treatment agent for type 1 and is typically administered via subcutaneous injection. Type 2 diabetes is a disease of insulin resistance by cells. Type 2 diabetes is the most common type of diabetes.
A woman has undergone a stem-cell therapy made from her own cells, to treat her type 1 diabetes. Researchers in China discovered the woman did not need to use insulin 75 days after the procedure ...
It is also used for the treatment of multidrug-resistant tuberculosis. [10] It is used by injection into a vein using an IV or into a muscle. [9] Amikacin, like other aminoglycoside antibiotics, can cause hearing loss, balance problems, and kidney problems. [9] Other side effects include paralysis, resulting in the inability to breathe. [9]
A fasting blood sugar level of ≥ 7.0 mmol / L (126 mg/dL) is used in the general diagnosis of diabetes. [17] There are no clear guidelines for the diagnosis of LADA, but the criteria often used are that the patient should develop the disease in adulthood, not need insulin treatment for the first 6 months after diagnosis and have autoantibodies in the blood.
Ad
related to: what is aminoglycoside therapy for diabetes 1